Biolipox completes aquisition from Inflazyme
Biolipox – with whom Orexo has reached an agreement under which Orexo will aquire Biolipox – completes the previously announced acquisition of the main part of the Canadian biopharma company Inflazymes research- and development assets.For detailed information, visit www.biolipox.com.For more information, please contact:Torbjörn Bjerke, President and CEO, Biolipox AB+46 (0)708-66 19 90, e-mail: torbjorn.bjerke@biolipox.comClaes Wenthzel, Executive VP and CFO, Orexo AB+46 (0)18 780 88 44, +46 (0)708-62 01 22 , e-mail: claes.wenthzel@orexo.com